The results of the subgroup analysis showed that in advanced EGFR-mutant NSCLC patients who had smoked previously, in advanced EGFR-mutant NSCLC, the addition of an angiogenesis inhibitor to EGFR TKI therapy resulted in statistically significant PFS and OS benefits that were comparable to those of EGFR-TKI alone, which is in contrast to the results of EGFR-TKI alone in the treatment of advanced NSCLC [30–32]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.